Newer Therapies to Optimize Outcomes
in Patients with Chronic Kidney Disease

Tuesday, May 9, 2023

Breakfast: 6:30PM - 7:00AM PST
Symposium: 7:00PM - 8:30AM PST

Venue: Palm Springs Convention Center
Ballroom: Oasis 3A
Palm Springs, California


Faculty:
Molly Cahill, APRN, BC, NP-C, CNN;
Debra Castner, RN, MSN, APN, CNN;
David Cherney, MD CM, PhD, FRCP(C);
Csaba Kovesdy, MD;

Registration for this program is now closed.

Clinical evidence has demonstrated that newer potassium binders and sodiumglucose cotransporter-2 (SGLT2) inhibitors can have a dramatic impact on outcomes of patients with chronic kidney disease (CKD). Potassium binders can not only effectively treat hyperkalemia, which can potentially be life-threatening, but very importantly enable CKD patients to continue taking life-saving reninangiotensin- aldosterone system inhibitor (RAASi) therapy. Furthermore, potassium binders can prevent the need for urgent rescue therapy to reduce serum potassium in end-stage renal disease (ESRD) patients undergoing adequate dialysis. SGLT2 inhibitors have demonstrated significant reductions in the progression of CKD as well as in cardiovascular risk in individuals with and without type 2 diabetes. It is therefore essential for nephrology nurses to not only be aware of the robust clinical data with these therapies but also play a critical role in the effective implementation of therapy, patient education, and adherence. Therefore, in this symposium, experts will interpret clinical evidence with these agents, and panel discussions will address prudent patient behaviors and fundamental knowledge for outcomes to be optimized.

Educational Objectives: 

1. Describe the association between hyperkalemia with CKD and ESRD
2. Interpret the data with newer potassium binders in individuals with CKD and ESRD undergoing adequate hemodialysis
3. Summarize, and provide evidence for, the efficacy and safety of SGLT2 inhibitors in patients with CKD for slowing the progression of kidney disease
4. Recognize the relationship between CKD and cardiovascular disease and heart failure, and explain cardiovascular data with SGLT2 inhibitors in clinical trials of patients with CKD
5. Discuss prudent behaviors of, and essential knowledge for CKD patients with hyperkalemia taking potassium binders and with individuals initiating SGLT2 inhibitor therapy

Learning Outcome Statement:
After completion of this learning activity, participants will be able to discuss optimizing outcomes in CKD patients related to new evidence concerning the use of new therapies for hyperkalemia management and SGLT2 inhibitors.

Accreditation Statement:
This educational activity is jointly provided by the American Nephrology Nurses Association (ANNA) and Voxmedia.
ANNA is a provider by the California Board of Registered Nursing, provider number CEP 1499.

Educational Grant:
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Target Audience: 
This educational activity is intended for nephrology nurses and other nurses and clinicians treating patients with chronic kidney disease.

ANCC Disclosure Statement:
Presenters reported the following relevant financial relationships in relation to this nursing professional development (NCPD) activity:
Cahill: Disclosed that she is a speaker for Amgen and Boehringer Ingelheim, and also is on the ad board for Boehringer Ingelheim. She also recently was a member of the ad board for Calliditas.
Castner: Disclosed that she is a member of the AstraZeneca speaker's bureau.
Cherney: Disclosed that he serves in consultant and/or speaking and/or advisory roles and has received honoraria from the following: Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk.
Kovesdy: Disclosed that he is a consultant for AstraZeneca, Bayer, Boehringer Ingleheim, Cara Therapeutics and GSK. He has previously been a consultant for Abbott, Akebia, CSL Behring, CSL Vifor and Rockwell.

Voxmedia Disclosures:
Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.